Black Diamond Therapeutics Ownership | Who Owns Black Diamond Therapeutics?

Overview Forecast RevenueFinancials Chart

Black Diamond Therapeutics Ownership Summary

Black Diamond Therapeutics is owned by 71.92% institutional investors, 0.62% insiders, and 27.46% retail investors. T. rowe price investment management is the largest institutional shareholder, holding 18.52% of BDTX shares. BB Biotech AG Ord is the top mutual fund, with 15.05% of its assets in Black Diamond Therapeutics shares.

BDTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Black Diamond Therapeutics	71.92%	0.62%	27.46%
Sector	Healthcare Stocks	279.42%	10.64%	-190.05%
Industry	Biotech Stocks	64.05%	10.69%	25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	10.47M	18.52%	$22.40M
Bellevue group	8.52M	15.07%	$18.23M
Vestal point capital, lp	5.60M	9.91%	$11.98M
Nea management company	4.45M	7.87%	$9.52M
Blackrock funding, inc. /de	3.52M	6.23%	$7.53M
Blackrock	3.22M	6.21%	$14.99M
Vanguard group	2.41M	4.27%	$5.17M
Tang capital management	2.07M	3.66%	$4.43M
Artal group	1.05M	2.02%	$4.88M
Siren	1.05M	1.85%	$2.24M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Vestal point capital, lp	5.60M	0.71%	$11.98M
Nea management company	4.45M	0.54%	$9.52M
Bellevue group	8.52M	0.35%	$18.23M
Tang capital management	2.07M	0.29%	$4.43M
Affinity asset advisors	559.16K	0.16%	$1.20M
Artal group	1.05M	0.12%	$4.88M
Boxer capital	506.00K	0.12%	$2.36M
Siren	1.05M	0.10%	$2.24M
Dafna capital management	140.00K	0.08%	$299.60K
Kennedy capital management	433.79K	0.02%	$928.32K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	3.22M	0.00%	1.84M
Tang capital management	2.07M	0.29%	700.00K
Renaissance	904.00K	0.00%	650.20K
Vestal point capital, lp	5.60M	0.71%	571.50K
Affinity asset advisors	559.16K	0.16%	559.16K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-3.53M
Laurion capital management lp	-	-	-878.29K
Exoduspoint capital management, lp	-	-	-872.68K
Ally bridge group (ny)	-	-	-835.00K
Point72 asset management	-	-	-697.13K

New Positions

Holder	Shares	% Assets	Change	Value
Xtx topco	91.92K	0.02%	91.92K	$196.71K
Susquehanna fundamental investments	74.90K	0.00%	74.90K	$160.29K
Raymond james financial	24.99K	-	24.99K	$53.48K
Sei investments	22.80K	0.00%	22.80K	$48.80K
D. e. shaw	17.32K	-	17.32K	$37.06K

Sold Out

Holder	Change
Geowealth management	-26.00
Northwestern mutual wealth management	-35.00
Lindbrook capital	-83.00
Tsfg	-100.00
Farther finance advisors	-100.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	88	-1.12%	40,752,553	-14.93%	71	1.00%	32	-39.62%	31	82.35%
Dec 31, 2024	89	-21.93%	47,905,427	-1.67%	84	1.14%	53	-20.90%	17	-19.05%
Sep 30, 2024	113	21.51%	48,573,437	4.44%	85	1.07%	67	19.64%	20	11.11%
Jun 30, 2024	93	4.49%	46,507,345	18.77%	89	1.13%	56	12.00%	18	-18.18%
Mar 31, 2024	89	15.58%	39,156,127	2.72%	89	1.59%	50	31.58%	22	10.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	8.52M	15.05%	-
T. Rowe Price Small-Cap Stock	2.50M	4.40%	131.58K
T. Rowe Price US Small-Cap Core Equity	2.50M	4.40%	130.07K
T. Rowe Price Small-Cap Value	2.42M	4.25%	-2.83K
Vanguard US Total Market Shares ETF	1.33M	2.35%	-
Vanguard Total Stock Mkt Idx Inv	1.33M	2.34%	-
T. Rowe Price Instl Small-Cap Stock	1.28M	2.26%	48.61K
T. Rowe Price U.S. SC Core Eq Tr-D	1.26M	2.22%	46.68K
T. Rowe Price U.S. SC Value Eq Tr-D	1.25M	2.20%	6.86K
T. Rowe Price U.S. SC Value Eq Tr-Z	1.24M	2.19%	2.28K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$4.00M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$2.31M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$582.90K
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$2.07M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$837.16K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	7
2024 Q4	-	-
2024 Q3	-	1
2024 Q2	-	-

BDTX Ownership FAQ

Who Owns Black Diamond Therapeutics?

Black Diamond Therapeutics shareholders are primarily institutional investors at 71.92%, followed by 0.62% insiders and 27.46% retail investors. The average institutional ownership in Black Diamond Therapeutics's industry, Biotech Stocks , is 64.05%, which Black Diamond Therapeutics exceeds.

Who owns the most shares of Black Diamond Therapeutics?

Black Diamond Therapeutics’s largest shareholders are T. rowe price investment management (10.47M shares, 18.52%), Bellevue group (8.52M shares, 15.07%), and Vestal point capital, lp (5.6M shares, 9.91%). Together, they hold 43.51% of Black Diamond Therapeutics’s total shares outstanding.

Does Blackrock own Black Diamond Therapeutics?

Yes, BlackRock owns 6.21% of Black Diamond Therapeutics, totaling 3.22M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 14.99M$. In the last quarter, BlackRock increased its holdings by 1.84M shares, a 133.04% change.

Who is Black Diamond Therapeutics’s biggest shareholder by percentage of total assets invested?

Vestal point capital, lp is Black Diamond Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.71% of its assets in 5.6M Black Diamond Therapeutics shares, valued at 11.98M$.

Who is the top mutual fund holder of Black Diamond Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Black Diamond Therapeutics shares, with 15.05% of its total shares outstanding invested in 8.52M Black Diamond Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools